Immunology
What is the investment community excited about in 2022?
Breaking down the sector based on types of investment, 2022 is shaping up to be an exciting year for biotech investors, according to Gabriel Cavazos, senior managing director of investment banking at SVB Leerink. Cavazos participated in a panel discussion on the outlook of biotech investments during Biotech Showcase. Read More
NETs-Th17 interaction offers new therapeutic target
Histones, a protein component of neutrophil extracellular traps (NETs), can directly stimulate T cells, specifically T helper 17 (Th17) cell differentiation, according to a recent Nature Communications research article. The stimulation of a specific adaptive immune cell subset imparts a noteworthy mechanism -- indicating a direct association between neutrophils, NETs, and T-cell autoimmunity -- and could be a new therapeutic target to treat autoimmune conditions. Read More
SLAS CEO shares what you need to know before you go to SLAS 2022
The Society for Laboratory Automation and Screening (SLAS) 2022 International Conference and Exhibition is taking place February 5-9 in Boston. Ahead of the event, SLAS CEO Vicki Loise shared some of the must-attend sessions and conference highlights with ScienceBoard. Read More
Despite volatility in biotech markets, investors remain enthusiastic
While the biotech markets are down to start 2022, there is an optimistic view among biotech investors, according to Camille Samuels, partner at Venrock, a venture capital firm. Samuels participated in a panel discussion at Biotech Showcase 2022 and spoke with ScienceBoard as part of Biotech Finance Month. Read More
Kevin DeGeeter in 5 questions, part of Biotech Finance Month 2022
Scientific innovation is happening at an ultrasonic rate these days, but what does this mean for cancer patients and their treatment options? This was the topic of "Outsmarting Cancer: Next Generation Therapies," a session at Biotech Showcase 2022. Kevin DeGeeter, managing director and senior analyst, biotechnology and diagnostics, at Oppenheimer, moderated the robust panel discussion and shared his insights with ScienceBoard as part of Biotech Finance Month 2022. Read More
CAR T-cell therapy collaborations expand cancer treatment options
Considering the broad range of the causes of cancer and the heavy impact on patients, advanced and innovative treatments are essential to fighting it. One technology being explored for this purpose is CAR T-cell therapy, because it trains the body's immune system to specifically target cancerous cells, according to Cell and Gene Therapy Business Outlook, a sister publication of ScienceBoard. Some healthcare institutions are collaborating with companies to develop such technologies, including Celularity, Lonza, and the Memorial Sloan Kettering Cancer Center. Read More
Roswell Biotechnologies demonstrates scalable molecular electronics chip
Roswell Biotechnologies and leading academic scientists have developed the first molecular electronics chip, realizing a 50-year-old goal of integrating single molecules into circuits to achieve the ultimate scaling limits of Moore's Law. Read More
BD innovation highlights new flow cytometry tech
A new study conducted by Becton Dickinson (BD) in collaboration with the European Molecular Biology Laboratory, which was published as the cover story of Science on January 20, profiles a BD innovation in flow cytometry that adds fluorescence imaging and image-based decisioning to sort individual cells at an exceptionally high speed. Read More
Targeted nanoparticle delivery provides boost for diabetes transplant
Delivering immunosuppressant treatment via targeted nanoparticles could open the door to a long-lasting cure for type 1 diabetes. Transplanting insulin-producing cells is a promising approach to treat the disease; however, it is plagued by issues of immune rejection. In a new study, published January 17 in Nature Nanotechnology, mice treated with a reengineered therapy could tolerate a transplant for much longer with fewer side effects. Read More
Developments in cell therapy boost potential for autoimmune disease treatments
Healthcare leaders are working together to change the therapeutic landscape for autoimmune diseases, which are often due to unknown causes, according to Cell and Gene Therapy Business Outlook, a sister publication of ScienceBoard. Atara Biotherapeutics, Kyverna Therapeutics, and the National Institutes of Health are a few organizations that are dedicated to finding treatments for patients with limited options. Read More
Conferences
International Society for Cell and Gene Therapy Annual Meeting
May 4 - June 7
San Francisco, California United States
American Society for Mass Spectrometry Annual Conference
June 5-9
Minneapolis, Minnesota United States
American Society for Microbiology Microbe Meeting
June 9-13
District of Columbia United States
HPLC 2022
June 18-23
San Diego, California United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter